Jump to ContentJump to Main Navigation
Race in a BottleThe Story of BiDil and Racialized Medicine in a Post-Genomic Age$
Users without a subscription are not able to see the full content.

Jonathan Kahn

Print publication date: 2014

Print ISBN-13: 9780231162999

Published to Columbia Scholarship Online: November 2015

DOI: 10.7312/columbia/9780231162999.001.0001

Show Summary Details
Page of

PRINTED FROM COLUMBIA SCHOLARSHIP ONLINE (www.columbia.universitypressscholarship.com). (c) Copyright University of Minnesota Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in CUPSO for personal use.date: 21 September 2021



Race and Medicine: Framing [Is] the Problem

(p.1) Introduction
Race in a Bottle

Leszek Koczanowicz

Columbia University Press

This introductory chapter explores the intersections of race, science, law, and commerce and shows how a larger scheme of institutional, legal, and commercial imperatives is shaping the use of race in biomedicine. The drug BiDil is used as an entry point into this study. BiDil is a combination of two generic drugs used to dilate blood vessels—hence “Bi” (two) and “Dil” (dilators). Its development into a racialized drug is worth taking into account—this study does so by unearthing five themes in BiDil's history and the overall issue of racialized medicine: the institutional mandates that promote the introduction of race into biomedical research and practice.

Keywords:   BiDil, biomedicine, race, racialized medicine, biomedical research, health disparities, racial injustice, genomic discovery

Columbia Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us .